194 related articles for article (PubMed ID: 37518950)
1. Biosynthesis of kratom opioids.
Kim K; Shahsavarani M; Garza-García JJO; Carlisle JE; Guo J; De Luca V; Qu Y
New Phytol; 2023 Oct; 240(2):757-769. PubMed ID: 37518950
[TBL] [Abstract][Full Text] [Related]
2. Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.
Wilson LL; Chakraborty S; Eans SO; Cirino TJ; Stacy HM; Simons CA; Uprety R; Majumdar S; McLaughlin JP
Cell Mol Neurobiol; 2021 Jul; 41(5):1131-1143. PubMed ID: 33433723
[TBL] [Abstract][Full Text] [Related]
3. Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products.
Manwill PK; Flores-Bocanegra L; Khin M; Raja HA; Cech NB; Oberlies NH; Todd DA
Planta Med; 2022 Aug; 88(9-10):838-857. PubMed ID: 35468648
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three chromatographic techniques for the detection of mitragynine and other indole and oxindole alkaloids in Mitragyna speciosa (kratom) plants.
Wang M; Carrell EJ; Ali Z; Avula B; Avonto C; Parcher JF; Khan IA
J Sep Sci; 2014 Jun; 37(12):1411-8. PubMed ID: 24659356
[TBL] [Abstract][Full Text] [Related]
5. Directed Biosynthesis of Mitragynine Stereoisomers.
Schotte C; Jiang Y; Grzech D; Dang TT; Laforest LC; León F; Mottinelli M; Nadakuduti SS; McCurdy CR; O'Connor SE
J Am Chem Soc; 2023 Mar; 145(9):4957-4963. PubMed ID: 36883326
[No Abstract] [Full Text] [Related]
6. Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
[TBL] [Abstract][Full Text] [Related]
7. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
Avery BA; Boddu SP; Sharma A; Furr EB; Leon F; Cutler SJ; McCurdy CR
Planta Med; 2019 Mar; 85(4):340-346. PubMed ID: 30452072
[TBL] [Abstract][Full Text] [Related]
8. G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder.
Gutridge AM; Robins MT; Cassell RJ; Uprety R; Mores KL; Ko MJ; Pasternak GW; Majumdar S; van Rijn RM
Br J Pharmacol; 2020 Apr; 177(7):1497-1513. PubMed ID: 31705528
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review.
Ya K; Tangamornsuksan W; Scholfield CN; Methaneethorn J; Lohitnavy M
Asian J Psychiatr; 2019 Jun; 43():73-82. PubMed ID: 31100603
[TBL] [Abstract][Full Text] [Related]
10. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
[TBL] [Abstract][Full Text] [Related]
11. An in vitro evaluation of kratom (Mitragyna speciosa) on the catalytic activity of carboxylesterase 1 (CES1).
Melchert PW; Zhang Q; Mukhopadhyay S; Kanumuri SRR; McCurdy CR; Markowitz JS
Chem Biol Interact; 2023 Oct; 384():110715. PubMed ID: 37716419
[TBL] [Abstract][Full Text] [Related]
12. Metabolite and Molecular Characterization of
Laforest LC; Kuntz MA; Kanumuri SRR; Mukhopadhyay S; Sharma A; O'Connor SE; McCurdy CR; Nadakuduti SS
J Nat Prod; 2023 Apr; 86(4):1042-1052. PubMed ID: 36913648
[TBL] [Abstract][Full Text] [Related]
13. Kratom (Mitragyna speciosa): worldwide issues.
Ramanathan S; McCurdy CR
Curr Opin Psychiatry; 2020 Jul; 33(4):312-318. PubMed ID: 32452943
[TBL] [Abstract][Full Text] [Related]
14. The effects of chronic mitragynine (Kratom) exposure on the EEG in rats.
Suhaimi FW; Hassan Z; Mansor SM; Müller CP
Neurosci Lett; 2021 Feb; 745():135632. PubMed ID: 33444671
[TBL] [Abstract][Full Text] [Related]
15. Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects.
Grundmann O; Hill K; Al Barzanji E; Hazrat NG; Kaur G; Negeve RE; Shade S; Weber S; Veltri CA
J Ethnopharmacol; 2023 Dec; 317():116779. PubMed ID: 37364801
[TBL] [Abstract][Full Text] [Related]
16. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric Total Syntheses of Mitragynine, Speciogynine, and 7-Hydroxymitragynine.
Sakamoto J; Kitajima M; Ishikawa H
Chem Pharm Bull (Tokyo); 2022; 70(9):662-668. PubMed ID: 36047237
[TBL] [Abstract][Full Text] [Related]
18. Drug testing for mitragynine and kratom: Analytical challenges and medico-legal considerations.
Helander A; Rylski A
Drug Test Anal; 2023 Feb; 15(2):213-219. PubMed ID: 36258649
[TBL] [Abstract][Full Text] [Related]
19. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions.
Todd DA; Kellogg JJ; Wallace ED; Khin M; Flores-Bocanegra L; Tanna RS; McIntosh S; Raja HA; Graf TN; Hemby SE; Paine MF; Oberlies NH; Cech NB
Sci Rep; 2020 Nov; 10(1):19158. PubMed ID: 33154449
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: present knowledge and future directions in perspective of pain.
Ramachandram DS; Damodaran T; Zainal H; Murugaiyah V; Ramanathan S
J Basic Clin Physiol Pharmacol; 2019 Oct; 31(1):. PubMed ID: 31665120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
